Abstract：
OBJECTIVE: Schizophrenia (SZ) and bipolar disorders (BP) are chronic and severe neuropsychiatric diseases. These disorders are tightly related to immune deregulations. In the current study, we intended to replicate the previously reported involvement of the soluble HLA-E isoforms (sHLA-E) in the risk of developing the two conditions along with disease severity in a Tunisian population group.
METHODS: One hundred and twenty-four patients with schizophrenia and 121 with bipolar disorder meeting the DSM-IV criteria along 111 healthy controls were included in this present case-control study. The soluble HLA-E isoforms circulating levels were measured using the ELISA method. The statistical analyses were performed using Kruskal-Wallis and Wilcoxon rank sum tests by R software and GraphPad prism 9.
RESULTS: We found that the sHLA-E circulating levels were significantly higher in BP patients as compared to healthy controls (P<0.0001) and that such increases were mainly observed in patients during an acute phase of their disease (P<0.0001). In SZ patients, while we failed to observe an association with the levels of sHLA-E in the entire SZ sample, we found that high sHLA-E levels characterized stabilized patients in comparison with those during an acute episode (P=0.022). Finally, we did not observe any association between sHLA-E circulating levels and symptoms assessed by the classical clinical scales either in BP or SZ patients.
CONCLUSIONS: Overall, the present findings replicate in a Tunisian population group the previously demonstrated implication of sHLA-E circulating levels in the risk of developing BP or SZ in a French patient cohort. Such replication allows to consider HLA-E as a potent and true inflammatory marker in the context of the two disorders.
METHODS: One hundred and twenty-four patients with schizophrenia and 121 with bipolar disorder meeting the DSM-IV criteria along 111 healthy controls were included in this present case-control study. The soluble HLA-E isoforms circulating levels were measured using the ELISA method. The statistical analyses were performed using Kruskal-Wallis and Wilcoxon rank sum tests by R software and GraphPad prism 9.
RESULTS: We found that the sHLA-E circulating levels were significantly higher in BP patients as compared to healthy controls (P<0.0001) and that such increases were mainly observed in patients during an acute phase of their disease (P<0.0001). In SZ patients, while we failed to observe an association with the levels of sHLA-E in the entire SZ sample, we found that high sHLA-E levels characterized stabilized patients in comparison with those during an acute episode (P=0.022). Finally, we did not observe any association between sHLA-E circulating levels and symptoms assessed by the classical clinical scales either in BP or SZ patients.
CONCLUSIONS: Overall, the present findings replicate in a Tunisian population group the previously demonstrated implication of sHLA-E circulating levels in the risk of developing BP or SZ in a French patient cohort. Such replication allows to consider HLA-E as a potent and true inflammatory marker in the context of the two disorders.
摘要：
目的：精神分裂症（SZ）和双相情感障碍（BP）是慢性和严重的神经精神疾病。这些疾病与免疫失调密切相关。在目前的研究中,我们打算在突尼斯人群中复制先前报道的可溶性HLA-E亚型(sHLA-E)参与两种疾病发展的风险以及疾病严重程度.
方法：本病例对照研究包括111名健康对照中符合DSM-IV标准的124名精神分裂症患者和121名双相情感障碍患者。使用ELISA方法测量可溶性HLA-E同种型循环水平。通过R软件和GraphPad棱镜9使用Kruskal-Wallis和Wilcoxon秩和检验进行统计分析。
结果：我们发现，与健康对照组相比，BP患者的sHLA-E循环水平明显更高（P<0.0001），并且这种增加主要在患者的急性期观察到疾病（P<0.0001）。在SZ患者中，虽然我们未能观察到整个SZ样本中sHLA-E水平的相关性，我们发现,与急性发作期相比,高sHLA-E水平是稳定患者的特征(P=0.022).最后,在BP或SZ患者中,我们未观察到sHLA-E循环水平与通过经典临床量表评估的症状之间存在任何关联.
结论：总体而言，本研究结果在突尼斯人群组中重复了先前证明的sHLA-E循环水平对法国患者队列中发生BP或SZ的风险的影响.这样的复制允许将HLA-E视为在这两种病症的背景下有效且真实的炎性标记。
方法：本病例对照研究包括111名健康对照中符合DSM-IV标准的124名精神分裂症患者和121名双相情感障碍患者。使用ELISA方法测量可溶性HLA-E同种型循环水平。通过R软件和GraphPad棱镜9使用Kruskal-Wallis和Wilcoxon秩和检验进行统计分析。
结果：我们发现，与健康对照组相比，BP患者的sHLA-E循环水平明显更高（P<0.0001），并且这种增加主要在患者的急性期观察到疾病（P<0.0001）。在SZ患者中，虽然我们未能观察到整个SZ样本中sHLA-E水平的相关性，我们发现,与急性发作期相比,高sHLA-E水平是稳定患者的特征(P=0.022).最后,在BP或SZ患者中,我们未观察到sHLA-E循环水平与通过经典临床量表评估的症状之间存在任何关联.
结论：总体而言，本研究结果在突尼斯人群组中重复了先前证明的sHLA-E循环水平对法国患者队列中发生BP或SZ的风险的影响.这样的复制允许将HLA-E视为在这两种病症的背景下有效且真实的炎性标记。
